Altered prefrontal cortical function during processing of fear-relevant stimuli in pregnancy

In non-pregnant individuals, the prefrontal cortex (PFC) is involved in the regulation of emotion, and appears to play a role in anxiety. Near-infrared spectroscopy (NIRS) detects cortical neural activation without harmful radiation making it safe for use in pregnancy. The aims of this study were to assess neural circuitry involved in processing fear-relevant stimuli during pregnancy using NIRS, and to determine associations between activation of this circuitry, distress and anxiety symptoms, attention to threat, cortisol, estrogen, progesterone and testosterone levels. There was significant activation of the PFC in response to fearful faces compared to rest in both pregnant and control groups. Within pregnancy, the activation was most pronounced at trimester 2, compared to the other trimesters. In pregnant women only (all trimesters), PFC activation was significantly associated with increased distress and anxiety, but with decreased selective attention to masked fear. PFC activation was also significantly associated with increased levels of cortisol and testosterone in pregnancy. PFC function appears to be altered during processing of fear-relevant stimuli in pregnancy. Changes in hormone levels may lead to changes in PFC function, and in turn to changes in cognitive-affective processing and anxiety. Further work is needed, however, to explore precisely how PFC function is altered in pregnancy; it is possible that certain changes reflect altered processing of threat stimuli, while others reflect attempts to compensate for distressing and anxious symptoms that emerge during pregnancy.

Abstract P4-04-05: Histone Deacetylase Inhibitors Increase Markers of the Dedifferentiated Cancer Stem Cell Phenotype in Human Breast Cancer Cells

It has been suggested that differentiated cancer cells can de-differentiate into the cancer stem cell phenotype (Meyers et al., 2009; Gupta et al., 2009) and that Histone Deacetylase (HDAC) inhibitors enable efficient induction of pluripotent stem cells from adult fibroblasts (Huangfu et al., 2009). Moreover, we have recently demonstrated that the HDAC inhibitor valproic acid radiosensitized breast cancer cells grown on plastic with serum while it radioprotected breast cancer cells grown in stem cell promoting culture conditions (Debeb et al., 2010). Based on these data, we hypothesized that HDAC inhibitors increase the cancer stem cell population via dedifferentiation of differentiated cancer cells. To examine our hypothesis, Sum159 breast cancer cells were FACS-sorted based on ALDH activity and subsequently treated with one of two HDAC inhibitors, valproic acid or SAHA (suberoylanilide hydroxamic acid). After sorting, ALDH-negative cells were treated either with valproic acid, SAHA, or vehicle. After a week, the percentage of ALDH-positive cells (passage 0, P0) was examined with flow cytometry while the remaining cells were passaged and incubated with and without valproic acid or SAHA for a week and the percentage of ALDH-positive cells again evaluated (P1). This was repeated for the third time (P2). Samples from each generation were also collected to examine the protein expression. On average, a 3-fold increase in ALDH positive cells was seen in valproic acid-treated cells (35.6% vs.12.6%) and a 1.5-fold increase in SAHA-treated cells (41% vs. 28%) compared to vehicle-treated controls. This effect was maintained through multiple passages. Moreover, the expression of Beta-catenin and EMT associated genes like vimentin, fibronectin, n-cadherin, which have been implicated in generating cancer stem cells was significantly increased withtreatment in initial and passaged cells. Further functional endpoint studies are needed to validate these in vitro marker-based findings.

Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-04-05.

p53 Mutation in Inflammatory Breast Cancer Cell Lines

Background: Inflammatory breast cancer (IBC) is the most aggressive manifestation of primary breast cancer and represents 1% to 2% of primary breast cancer in the United States. IBC is characterized by an acute inflammation of the skin of the affected breast generally believed to be caused by blockage of the dermal lymphatics by tumor emboli. Wild type (WT) p53 is a tumor suppressor gene, which induces apoptosis and p53 mutations are associated with poor prognosis in breast cancer. Compared with locally advanced breast cancers, IBC patients have higher levels of mutated p53 protein that has been associated with more aggressive tumors, anthracycline resistance, shorter progression free survival, shorter overall survival, and less favorable long-term outcome. The aim of this study was to determine if there are unique genetic variations in IBC cell lines that would provide specific genetic p53 mutations that could be exploited for targeted therapy with the intent of improving response to treatment and overall survival in IBC.Materials and Methods: Genomic DNA was extracted from six breast cancer cell lines (MDA-453, SUM149, MCF-7, KPL4, MDA321, and SUM190) and the immortalized human mammary epithelial cells (HMLE) using the Qiagen DNA Blood Mini Kit (Valencia, CA). Among the 6 breast cancer cell lines, KPL-4, SUM149 and SUM190 are IBC cell lines; MDA231 and SUM149 have basal-like phenotype; MCF-7 has wild-type p53; SUM190 and KPL-4 are Her2 amplified. The DNA purity and concentration were determined by spectrophotometric measurements of absorbance at 260nm and 280 nm. Polymerase chainreaction (PCR) was performed to amplify the fragments of exons 2-11 of the p53gene using consensus primers. The PCR products were scanned and identified using the Agilent Bioanalyzer 2100. DNA sequencing was performed on PCR products in the ABI PRISM 310 Genetic Analyzer. The BLAST search was used to identify p53 mutations compared with the reference sequence, X54156, from Genbank.Results: We screened 2-11 exon sequences of the p53 gene in the 7 human breast cell lines. We identified two IBC cell lines (SUM149, SUM-190) with a p53 gene alteration that predicted a change in the encoded protein, SUM149 at exon 7 (ATG to ATA, Met-237-Ile) and SUM190 at exon 9 (CAG to TAG, Gln -317-stop). Both mutations have been previously reported. Five nonsense mutations were identified in two other cell lines, MDA-453 and MDA321. No mutations were identified in KPL4 and HMLE cells.Conclusions: The p53 mutation profile in breast cancer cell lines suggests an additional biological feature for the characterization of IBC. Furthermore, these data support the previously reported association between p53 status and chemo- and radioresistance in this disease responsible for poor prognosis. Therapies directed to restore p53 function should be explored in IBC models and in clinical trials.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3161.

Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: a novel approach to suppressing metastasis

Abstract #2042

Background: Inflammatory breast cancer (IBC) is a rare subtype well known for its propensity for rapid metastasis. The cause of this rapid metastasis in IBC is unknown. An immunohistochemical analysis of 44 cases of IBC showed HER2 overexpression in 48% of patients and epidermal growth factor receptor (EGFR) overexpression in 30% of patients. EGFR overexpression was the only poor prognostic factor: the 5-year overall survival rate was significantly lower for women with EGFR-positive disease than for women with EGFR-negative disease (P=0.01). HER2 overexpression was not a prognostic factor. The association between EGFR overexpression and increased risk of death indicated that EGFR may represent a potential therapeutic target in IBC. We hypothesized that suppression of the EGFR pathway inhibits proliferation and metastasis of IBC.
 Methods: SUM149 IBC cells, which express low levels of HER2 and high levels of EGFR, were treated with siRNA against EGFR and with the EGFR tyrosine kinase inhibitor erlotinib.
 Results: EGFR siRNA knockdown (but not non-targeting siRNA control) inhibited the proliferation of SUM149 cells. SUM149 cells were sensitive to EGFR tyrosine kinase inhibitor erlotinib in a 2-dimensional (2-D) culture system (median inhibitory concentration [IC50] = 0.90 µM). When we activated ERK by transfecting constitutively active MEK1 in SUM149 cells, the cells showed more resistance to erlotinib. Moreover, ERK siRNA knockdown sensitized SUM149 cells to erlotinib. Further, when we cultured the SUM149 cells in matrigel by using the 3-D culture system (100% matrigel in the bottom layer and cultured medium with 5% FBS and 2% matrigel in the top layer), erlotinib treatment changed the molecular phenotype of SUM149 cells from mesenchymal (a phenotype characterized by low beta-catenin expression and high vimentin and fibronectin expression) to epithelial (recovery of beta-catenin to the sites of cell-cell contacts; downregulation of fibronectin). This reversal of the mesenchymal phenotype, a hallmark of inhibition of epithelial-to-mesenchymal transition (EMT), was ERK dependent. Interestingly, the erlotinib concentration that inhibited the mesenchymal phenotype (0.1 mcM) was one log lower than the concentration that inhibited proliferation (1 mcM).
 Conclusion: Inhibition of tumor growth and EMT in SUM149 IBC cell lines is dependent on the ERK pathway through the EGFR pathway. The erlotinib dose needed to produce an anti-mesenchymal effect is much lower than the cytotoxic dose. Thus, we speculate ERK pathway to be important in inhibiting metastasis in IBC. We are currently investigating the effects of erlotinib in a xenograft model of IBC. Our study provides a rationale for developing novel treatment strategies targeting the EGFR and ERK pathways to inhibit the growth and metastasis of IBC.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2042.

A multistage nanodelivery system for therapeutic applications and medical imaging: in vivo biodistribution and efficacy study in a murine orthotopic breast cancer model

Abstract #2160

The ability to deliver therapeutic compounds specifically to diseased sites is crucial for effectively treating human illnesses. Nanotechnology is emerging as a tool for resolving challenges in the delivery of poorly administrable drugs by transforming them into nanometer-sized particles (nanotherapeutics). The progress thus far gave rise to a large number of nanotherapeutics, but the accomplishment of the original objective, which is to increase drug concentration at target sites, has not been fully realized. A series of biological barriers pose as insurmountable obstacles which limit or completely abolish the ability to selectively deliver a therapeutic agent. We hypothesized that a multi-stage system for systemic delivery (MSDS) could be designed to interact with and successfully overcome sequential biological barriers. We developed a MSDS using biodegradable, biocompatible silicon particles optimally sized and shaped to travel into the blood flow, avoid RES, marginate and adhere to tumor vasculature. The first stage carriers (FSCs) contain nanopores of specific size that can load, carry, release over time, and deliver multiple types of second stage nanoparticles (SSNs). The nanoparticles can be optimized to reach, through vessels fenestrations, the tumor environment and finally release their therapeutic payload into target cells.
 
 The ease in chemically modifying the silicon surface permits the attachment of fluorescent and radiolabeled imaging molecules to the FSCs. Fluorescent and magnetic SSNs can be loaded into the pores of the FSCs. Once assembled, the resulting MSDS can be imaged using different in vivo imaging modalities from its administration to its final localization into the body. We further modified our FSCs with PEG molecules to increase their circulation time and with antibodies directed against the VEGFR2 membrane protein to increase the localization of the MSDS in tumor associated vessels. We monitored the biodistribution of all MSDSs and characterized their biocompatibility in the different tissues. Finally, we loaded the pores of the FSCs with a lipidic nanoformulation of the potent anti cancer drug doxorubicin (dox-liposomes and dox-micelles) and followed the efficacy of this treatment. Taken together, these studies provide first time evidence that silicon nanoporous particles can be used as effective carriers for the simultaneous delivery of different nanotherapeutics in vivo.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2160.

Sources of phosphorus lost from a grazed pasture receiving simulated rainfall

Nutrients exported from grazing systems contribute to eutrophication of surface waters. In this study the contributions of soil, pasture-plants, and dung to P exports in overland flow were compared using simulated rainfall. The treatments were (i) grazed pasture-plants (isolated from soil by application of petrolatum to the soil surface), (ii) grazed pasture-plants and supporting soil, (iii) grazed pasture-plants and soil and treading, and (iv) grazed pasture-plants and soil and treading and dung. In general, dissolved reactive P (DRP) accounted for the majority of the P exported and P losses decreased in the order: treading and dung treatment>treading>pasture-plants and soil>pasture-plants. Very little dissolved organic P was lost in overland flow and the effects of treading diminished with time. Over a normal grazing cycle (30 d), the portion of P lost from pasture-plants was approximately half that lost from pasture-plants and soil, one-third that lost from treaded pasture-plants and soil, and one-quarter that lost from treaded pasture-plants, soil, and dung. The DRP in the pasture-plants treatment was approximately half that in the pasture-plants and soil treatment and suggests that a significant portion of the P exported from these systems is derived directly from pasture-plants. Due to higher proportions of particulate P (PP) in the treaded and dung treatments, DRP accounted for less of total P than in the pasture-plants and pasture-plants and soil treatments. Lower infiltration capacities probably caused by mechanical disaggregation at the soil surface are consistent with the higher proportions of PP in the treading treatments. These results were used to estimate P exports from a field trial site in Southland, New Zealand. The results suggested that P export attributable to fertilizer, dung, pasture-plants, and soil components were approximately 10, 30, 20, and 40%, respectively. These results suggest that since 90% of the P exports are derived from the soil-plant system and dung returns, managements to lessen P exports should continue to focus on maintaining soil P within the optimal range for pasture-plant production and maintaining soil surface properties that maximize infiltration and minimize overland flow.

Growing skull fracture in the absence of a dural tear

A case of growing skull fracture associated with unrecognized extradural haematoma is presented together with the relevant radiology. The pathophysiology of growing skull fracture is reviewed in light of this previously unreported case.

Two knees or not two knees? Patient costs and outcomes following bilateral and unilateral total knee joint replacement surgery for OA

AIMS

This study aims to address medical and non-medical direct costs and health outcomes of bilateral and unilateral total knee replacement from the patients' perspective during the first year post-surgery.

METHODS

Osteoarthritis patients undergoing primary unilateral total knee or bilateral total knee replacement (TKR) surgery at three Sydney hospitals were eligible. Patients completed questionnaires pre-operatively to record expenses during the previous three months and health status immediately prior to surgery. Patients then maintained detailed prospective cost diaries and completed SF-36 and WOMAC Index each three months for the first post-operative year.

RESULTS

Pre-operatively, no significant differences in health status were found between patients undergoing unilateral TKR and bilateral TKR. Both unilateral and bilateral TKR patients showed improvements in pain, stiffness and function from pre-surgery to 12 months post-surgery. Patients who had bilateral TKR spent an average of 12.3 days in acute hospital and patients who had unilateral TKR 13.6 days. Totally uncemented prostheses were used in 6% of unilateral replacements and 48% of bilateral replacements. In hospital, patients who had bilateral TKR experienced significantly more complications, mainly thromboembolic, than patients who had unilateral TKR. Regression analysis showed that for every one point increase in the pre-operative SF-36 physical score (i.e. improving physical status) out-of-pocket costs decreased by 94%. Out-of-pocket costs for female patients were 3.3 times greater than for males.

CONCLUSION

Patients undergoing bilateral TKR and unilateral TKR had a similar length of stay in hospital and similar out-of-pocket expenditures. Bilateral replacement patients reported better physical function and general health with fewer health care visits one year post procedure. Patients requiring bilateral TKR have some additional information to aid their decision making. While their risk of peri-operative complications is higher, they have an excellent chance of good health outcomes at 12 months and are not going to be doubly "out-of-pocket" for the experience.

Unbalanced growth in mouse cells with amplified dhfr genes

When grown in the absence of methotrexate, cells carrying unstably amplified dihydrofolate reductase (dhfr) genes have a growth disadvantage that is a function of their level of gene amplification. Although this growth disadvantage is thought to drive the loss of unstably amplified dhfr genes in the absence of methotrexate, its mechanism is not understood. The present studies of murine cell lines with different levels of dhfr gene amplification demonstrate that such cells experience increased unbalanced growth (excess RNA and protein content relative to DNA content) with increased levels of dhfr gene amplification. Stathmokinetic analysis of a cell line with unstably amplified dhfr genes showed that the unbalanced growth was associated with a very low rate of G1/S transit, which suggests that amplified DNA sequences may activate a cell cycle checkpoint at the G1/S boundary. Hydroxyurea, which is known to induce rapid elimination of amplified genes at sub-cytotoxic concentrations, also inhibits the cell cycle at the G1/S transition and causes unbalanced growth. Earlier work has shown that hydroxyurea selectively targets those cells within the heterogeneous drug resistant cell populations which have the highest amplified gene dosage. The finding that unstable gene amplification and hydroxyurea have similar effects on the cell suggests that hydroxyurea may achieve this selective targeting by pushing those cells with the highest levels of gene amplification over a critical stress threshold to cause growth arrest or cell death.

Scoring systems for grading deep leg vein thrombosis

A scoring system could be used in all situations where grading of deep leg vein thrombosis (DVT), including mapping of its distribution, is needed. It should also be used in epidemiological studies of DVT in further analysis of different risk groups suffering from DVT. Several scoring systems have been developed during the last three decades but have resulted in various complex and impractical systems. A scoring system should be easy to follow without any risk of misunderstanding and misinterpretation. All vein segments of importance should be defined and be possible to be included. This review describes and compares the scoring systems according to Marder et al., Arnesen et al., a subcommittee of venous disease and Björgell et al.

Radiology of the spleen

The spleen is generally not considered a challenge to the radiologist. Most often it poses a problem by anomalies or an irregular but normal contrast enhancement; however, a variety of inflammatory, infectious and neoplastic diseases may involve the spleen. CT and ultrasonography are screening modalities for the spleen. For problem solving, MR imaging can be helpful, especially due to its free choice of the imaging plane and because of the high resolution in contrast MR imaging. Splenic angiography as a diagnostic tool has generally been replaced by CT, ultrasound, or MR and is now used as an interventional method, e. g., in non-surgical management of patients with chronic idiopathic thrombocytopenia or in patients with splenic trauma. This article reviews the radiology of the spleen, including anatomy, embryology, splenomegaly, splenic injury, infarction, cysts, tumors, abscesses, sarcoidosis, and AIDS. Knowledge about the use of different imaging modalities and underlying gross and microscopic pathologic features leads to a better understanding of the radiologic findings.

40 years of the British Medical Association film competition

Since its inception in 1957 the BMA's annual film competition has fulfilled three roles--promoting the effective use of film and video in medical education, encouraging the production of high quality audiovisual material, and helping to increase the holdings of its film library. The BMA awards recognise programmes for their clinical accuracy, educational value and creative use of the medium.

Paths to Success

The Class of ′71 is a longitudinal study following the educational and career paths of a group of Australians over the years from secondary school to mid-adulthood. This article is the second of a two-part series detailing the results of this study. In Part 1, which appeared in the Spring 1995 edition of this journal, factors associated with career outcomes, measured 20 years after secondary school, were detailed. In this article, findings that relate to intergenerational mobility, the association of unemployment with career outcomes, the match between occupational aspirations and achievements, and factors the respondents believed were influential regarding career outcomes are reported.

Role of adhesion molecules in leukocyte binding to endothelial cells adherent to vascular grafts

BACKGROUND

The localization of leukocytes to vascular grafts is an essential part of healing and infection resistance. The mechanisms involved in this process are only partly understood.

STUDY DESIGN

Human saphenous vein endothelial cells (HSVEC) were grown on control polystyrene culture ware and expanded polytetrafluoroethylene (ePTFE). The binding of monoclonal antibodies against the intercellular adhesion molecule (ICAM-1) and the E-selectin by adherent HSVEC was determined by flow cytometry. Peripheral blood leukocytes (PBL) were cocultured with HSVEC adherent to ePTFE and leukocyte binding was determined with and without the addition of a protein kinase C inhibitor.

RESULTS

HSVEC adherent to ePTFE constitutively bound anti-ICAM-1 antibodies, which were attenuated by the protein kinase C inhibitor, H-7. HSVEC adherent to ePTFE bound significantly greater numbers of leukocytes than those on control (58 versus 41 percent, p < 0.05). Incubation with H-7 decreased leukocyte binding to HSVEC significantly (p < 0.005). Coculture of PBL with HSVEC adherent to ePTFE caused a tenfold increase in binding of anti-E-selectin antibodies (p < 0.0005).

CONCLUSIONS

These data indicate that PBL binding to HSVEC adherent to ePTFE is, at least in part, ICAM-1 to HSVEC adherent to ePTFE is, at least in part, ICAM-1 and E-selection dependent.

Isolation and Structure Determination of Demethylchodatin—a New Lichen Xanthone

The structure of demethylchodatin, a xanthone from the lichen Lecanora pachysoma, has been established by X-ray analysis of the corresponding triacetate derivative. Crystals of demethylchodatin triacetate are monoclinic, P 21/a, a 10.120(3), b 11.278(3), c 19.173(4) Ǻ, β 94.68(3)°; Z 4. Refinement of 1411 data with I > 3σ(I) gave conventional R factors of 0.041 and 0.033.

Expression of the 40 kD protein in DLD-1 colon cancer cells and the effect of cytokines

We recently reported the presence of an organ-specific 40 kD colonic protein which acts as an autoantigen(s) in patients with ulcerative colitis. Using a specific monoclonal antibody directed against 40 kD protein (7E12H12, IgM isotype), in conjunction with immunocytochemistry and flow cytometry, we examined the presence of the 40 kD protein on human colon cancer cells, DLD-1, and also characterized the ability of cytokines, IFN-gamma and tumour necrosis factor, to modulate the expression of this protein on these tumour cells. The presence of the 40 kD protein was localized to the plasma membrane; less was present within the cytoplasm. Following exposure to IFN-gamma (10-1000 U/ml), DLD-1 colon tumour cells showed a dose- and time-dependent increase in 7E12H12 antibody associated immunofluorescence, with the maximum 7E12H12 antibody binding observed with 100 U/ml IFN-gamma at 48 h. In contrast, tumour necrosis factor did not alter the levels of anti-40 kD antibody binding over that of control cells. Since IFN-gamma is also known to induce class II major histocompatibility antigens, we examined the possibility of cross-reactivity of HLA class II antigens and Mr 40 kD epitope. Neither pre-incubation of DLD-1 colon tumour cells with anti-HLA class II antibodies followed by 7E12H12 nor co-incubation of both antibodies altered the amount of 7E12H12 antibody binding. Using a direct ELISA, a highly enriched preparation of Mr 40 kD protein reactive to anti-40 kD antibody did not react with HLA class II antibodies. The present results suggest that 40 kD protein is present on DLD-1 human colon tumour cells and that although the 40 kD protein epitope expression is increased by the lymphocyte-derived cytokine, IFN-gamma, the epitope is separate and distinct from the class II HLA antigens. Further studies on the 40 KD protein may elucidate its autoantigenic role in the pathogenesis of inflammatory bowel disease.

Stimulatory effects of FK156 in a panel of tests designed to detect changes in immune function

There is a need to evaluate the utility of experimental models in immune function assessment if these are to be accepted in preclinical safety studies. We have evaluated a panel of tests measuring cellularity and functions of the lymphoid system in the Fischer rat in order to determine whether they would detect immunostimulation, rather than suppression. Injection of the peptide immunostimulant FK156 (D-lactyl-L-alanyl-y-D-glutamyl-(L)-meso-diaminopimelyl- (L)-glycine) increased the numbers of macrophages recovered from the peritoneal cavity, and stimulated their activity, as measured by chemiluminescence, adherence, and secretion of interleukin 1. In vitro, T lymphocytes had an increased background incorporation of tritiated thymidine, increased response to sub-optimal concentrations of concanavalin A, and an increase in secretion of interleukin 2 at optimal concentrations of concanavalin A. There was no change in the proliferative responses of B lymphocytes in vitro. Antibody responses to tetanus toxoid in vivo were increased. These changes were not reflected in consistent, statistically significant alterations in the numbers of lymphocytes bearing either lineage markers or the interleukin 2 receptor as a marker of activation.

A classification of prescription errors

Three independent methods of study of prescription errors led to the development of a classification of errors based on the potential effects and inconvenience to patients, pharmacists and doctors. Four types of error are described: type A (potentially serious to patient); type B (major nuisance - pharmacist/doctor contact required); type C (minor nuisance - pharmacist must use professional judgement); and type D (trivial). The types of frequency of errors are detailed for a group of eight principals from one health centre. There were a total of 504 errors from 15,916 prescription items (3.17%) during a three month observation period. A close correspondence was found between individual doctor's types of error rates, suggesting that doctors who make type C and D errors are also likely to make type B (major nuisance) errors. A system of feedback of errors from each doctor was devised. No significant reduction was seen in error rates, possibly because the group of self selected doctors taking part had low error rates initially. It is suggested that pharmacists and doctors should work closely together to prevent the potentially harmful consequences of prescription errors.